The company is not selling any resale shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of resale shares by the selling stockholders.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- 3 Stocks to Buy Now, 12/2/2024, According to Corporate Insiders
- Neurogene Adjusts Clinical Trial After Setback
- Neurogene price target lowered to $45 from $60 at BMO Capital
- Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
- Neurogene price target lowered to $46 from $72 at Baird